Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes

Virology

Volumn 244, Issue 2, 1998, Pages 352-364

  Doan, Tracy ^a   Chambers, Melita ^b   Street, Michael ^a   Fernando, Germain J P ^b   Herd, Karen ^a   Lambert, Paul ^c   Tindle, Robert ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EPITHELIUM CELL; IMMUNOLOGICAL TOLERANCE; KERATINOCYTE; MOUSE; NONHUMAN; ONCOGENE; OPEN READING FRAME; PRIORITY JOURNAL; TARGET CELL; TRANSGENE; VIRUS EXPRESSION; WART VIRUS;

ANIMALIA; DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; MURINAE; MUS MUSCULUS;

EID: 0032503236     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9128     Document Type: Article

References (40)

1. Altmann A., Jochmus Kudielka I., Frank R., Gausepohl H., Moebius U., Gissmann L., Meuer S. C. Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7. Eur. J. Cancer. 28:1992;326-333.
2. Arbeit J. M., Munger K., Howley P. M., Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 68:1994;4358-4368.
3. Auewarakul P., Gissmann L., Cid Arregui A. Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors. Mol. Cell Biol. 14:1994;8250-8258.
4. Bal V., McIndoe A., Denton G., Hudson D., Lombardi G., Lamb J., Lechler R. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur. J. Immunol. 20:1990;1893-1897.
5. +b. Eur. J. Immunol. 25:1995;1932-1942.
6. Bleul C., Muller M., Frank R., Gausepohl H., Koldovsky U., Mgaya H. N., Luande J., Pawlita M., ter Meulen J., Viscidi R. Human papillomavirus type 18 E6 and E7 antibodies in human sera: Increased anti-E7 prevalence in cervical cancer patients. J. Clin. Microbiol. 29:1991;1579-1588.
7. Borysiewicz L. K., Fiander A., Nimako M., Man S., Wilkinson G. W., Westmoreland D., Evans A. S., Adams M., Stacey S. N., Boursnell M. E., Rutherford E., Hickling J. K., Inglis S. C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [see comments]. Lancet. 347:1996;1523-1527.
8. Bosch F. X., Manos M. M., Munoz N., Sherman M., Jansen A. M., Peto J., Schiffman M. H., Moreno V., Kurman R., Shah K. V. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments]. J. Natl. Cancer Inst. 87:1995;796-802.
9. Chen L., Ashe S., Singhal M. C., Galloway D. A., Hellstrom I., Hellstrom K. E. Metastatic conversion of cells by expression of human papillomavirus type 16 E6 and E7 genes. Proc. Natl. Acad. Sci. USA. 90:1993;6523-6527.
10. Coussens L. M., Hanahan D., Arbeit J. M. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am. J. Pathol. 149:1996;1899-1917.
11. Coutinho A. Simple developmental programs of gene expression and cellular composition of lymphoid organs at the origin of natural tolerance. Res. Immunol. 146:1995;321-332.
12. Doherty P. C. Anatomical environment as a determinant in viral immunity. J. Immunol. 155:1995;1023-1027.
13. Dunn L. A., Evander M., Tindle R. W., Bulloch A. L., de Kluyver R. L., Fernando G. J. P., Lambert P. F., Frazer I. H. Presentation of the HPV16E7 protein by skin grafts is sufficient to allow graft rejection in an E7-primed animal. Virology. 235:1997;94-103.
14. Feltkamp M. C., Smits H. L., Vierboom M. P., Minnaar R. P., de Jongh B. M., Drijfhout J. W., ter Schegget J., Melief C. J., Kast W. M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 23:1993;2242-2249.
15. 2a. Vaccine. 13/15:1995;1460-1467.
16. Fossum C., Bergstrom M., Lovgren K., Watson D. L., Morein B. Effect of iscoms and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: Comparison of spleen cells from mice inoculated with iscoms and/or matrix. Cell Immunol. 129:1990;414-425.
17. Frazer I. H., Leippe D. M., Dunn L. A., Liem A., Tindle R. W., Fernando G. J., Phelps W. C., Lambert P. F. Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Res. 55:1995;2635-2639.
18. Gotch F., Rothbard J., Howland K., Townsend A., McMichael A. Cytotoxic T lymphocytes recognise a fragment of fluenza virus matrix protein in association with HLA.A2. Nature. 326:1987;881-882.
19. Griep A. E., Herber R., Jeon S., Lohse J. K., Dubielzig R. R., Lambert P. F. Tumorigenicity by human papillomavirus type 16 E6 and E7 in transgenic mice correlates with alterations in epithelial cell growth and differentiation. J. Virol. 67:1993;1373-1384.
20. Herber R., Liem A., Pitot H., Lambert P. F. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J. Virol. 70:1996;1873-1881.
21. Herd K., Fernando G. J., Dunn L. A., Frazer I. H., Lambert P., Tindle R. W. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B-or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein. Virology. 231:1997;155-165.
22. Hoffmann M. W., Allison J., Miller J. F. Tolerance induction by thymic medullary epithelium. Proc. Natl. Acad. Sci. USA. 89:1992;2526-2530.
23. Hoffmann M. W., Heath W. R., Ruschmeyer D., Miller J. F. Deletion of high-avidity T cells by thymic epithelium. Proc. Natl. Acad. Sci. USA. 92:1995;9851-9855.
24. Kawai K., Ohashi P. S. Immunological function of a defined T-cell population tolerized to low-affinity self antigens [published erratum appears in Nature 1995 Nov 23;378(6555):419]. Nature. 374:1995;68-69.
25. Laufer T. M., DeKoning J., Markowitz J. S., Lo D., Glimcher L. H. Unopposed positive selection and autoreactivity in mice expressing class II MHC only on thymic cortex. Nature. 383:1996;81-85.
26. Melero I., Singhal M. C., McGowan P., Haugen H. S., Blake J., Hellstrom K. E., Yang G., Clegg C. H., Chen L. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. 71:1997;3998-4004.
27. Miller J. F., Heath W. R., Allison J., Morahan G., Hoffmann M., Kurts C., Kosaka H. T cell tolerance and autoimmunity. Ciba Found. Symp. 204:1997;159-168.
28. Modigliani Y., Coutinho A., Pereira P., Le Douarin N., Thomas Vaslin V., Burlen Defranoux O., Salaun J., Bandeira A. Establishment of tissue-specific tolerance is driven by regulatory T cells selected by thymic epithelium. Eur. J. Immunol. 26:1996;1807-1815.
29. Moore M., Carbone F. R., Bevan M. J. Introduction of soluble protein into class 1 pathway of antigen processing and presentation. Cell. 54:1988;777-785.
30. Munger K. The molecular biology of cervical cancer. J. Cell Biochem. 23:1995;55-60.
31. Oehen S. U., Ohashi P. S., Burki K., Hengartner H., Zinkernagel R. M., Aichele P. Escape of thymocytes and mature T cells from clonal deletion due to limiting tolerogen expression levels. Cell. Immunol. 158:1994;342-352.
32. Ressing M. E., Sette A., Brandt R. M., Ruppert J., Wentworth P. A., Hartman M., Oseroff C., Grey H. M., Melief C. J., Kast W. M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154:1995;5934-5943.
33. Ressing M. E., van Driel W. J., Celis E., Sette A., Brandt M. P., Hartman M., Anholts J. D., Schreuder G. M., ter Harmsel W. B., Fleuren G. J., Trimbos B. J., Kast W. M., Melief C. J. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res. 56:1996;582-588.
34. Tindle R. W., Fernando G. J., Sterling J. C., Frazer I. H. A 'public' T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc. Natl. Acad. Sci. USA. 88:1991;5887-5891.
35. Tindle R. W., Croft S., Herd K., Malcolm K., Geczy A. F., Stewart T., Fernando G. J. A vaccine conjugate of 'SCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin. Exp. Immunol. 101:1995;265-271.
36. Tindle R. W. Vaccines for cervical cancer. Curr. Opin. Immunol. 8:1996;643-650.
37. Tripp R. A., Hou S., McMickle A., Houston J., Doherty P. C. Recruitment and proliferation of CD8+ T cells in respiratory virus infections. J. Immunol. 154:1995;6013-6021.
38. Vitiello A., Marchesini D., Furze J., Sherman L. A., Chesnut R. W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1991;1007-1015.
39. von Herrath M. G., Dockter J., Nerenberg M., Gairin J. E., Oldstone M. B. Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus. J. Exp. Med. 180:1994;1901-1910.
40. von Knebel Doeberitz M., Rittmuller C., Aengeneyndt F., Jansen Durr P., Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: Consequences for the phenotype and E6-p53 and E7-pRB interactions. J. Virol. 68:1994;2811-2821.